

Vascular activity of protopanaxadiol and protopanaxatriol, the major saponin fractions isolated from roots of *Panax notoginseng*

Rosette Uzayisenga^{1,2*}, Yi Wang¹, Yu Ren¹, Peter Amwoga Ayeka^{1,3}, Pramod Singh Kunwar², Epaphrodite Twahirwa²

ABSTRACT

Background: *Panax notoginseng* (PN) (Burk) F. H. Chen (Araliaceae) is a Chinese herb commonly known in Asia for its medicinal potentials, antihypertensive included. The aim of this study was to investigate the vasorelaxant activity of protopanaxadiol (PDS) and protopanaxatriol (PTS), the major saponin fractions isolated from roots of PN, and identify the underlying mechanisms on isolated rat aortic rings. **Methods:** Radnoti Tissue-Organ bath instrument (ADInstruments) was used to perform Tissue-Organ bath experiments, and tensions produced on isolated rat aortic rings were recorded by the help of ADInstruments PowerLab 8/30 system (Model ML 870, Australia). **Results:** Both PDS and PTS (10^{-6} – 10^{-3} µg/ml) induced concentration-dependent relaxations in intact rat aortic rings pre-contracted with norepinephrine (1 µM). This activity was considerably reduced after removal of the endothelium and in intact rings pre-treated with N^G-nitro-L-arginine methyl ester (L-NAME, 100 µM), 1H-[1,2,4]-oxadiazole-[4,3- α]-quinoxaline-1-one (ODQ, 10 µM), and combination of L-NAME and ODQ. However, pre-treatment with indomethacin (10 µM) did not affect either PDS- or PTS-induced relaxations. Furthermore, both PDS and PTS (10^{-4} and 10^{-3} µg/ml) decreased CaCl₂- and potassium chloride (KCL)-induced vasoconstrictions in a dose-dependent manner. Our findings suggest that both PDS and PTS produced vasorelaxant effect that was mediated by NO-cyclic guanosine monophosphate in intact rings and by blockade of calcium influx in vascular smooth muscle. Cyclooxygenase pathway, on the other hand, had no apparent role. Among these fractions, PDS showed better effect with a slight difference. **Conclusion:** Findings from this study showed that both PDS and PTS fractions possess vasorelaxant activity. This supports the potential use of PN in management of cardiovascular diseases, especially hypertension.

KEY WORDS: Cardiovascular disease, *Panax notoginseng*, Protopanaxadiol, Protopanaxatriol, Vascular relaxation

BACKGROUND

Cardiovascular disease (CVD), which encompasses a spectrum of diseases including hypertension, is perennial among the leading causes of morbidity and mortality worldwide.^[1-6] Many CVDs are pathophysiologically associated with deficiency of nitric oxide (NO) in the heart and blood vessels.^[7] The regulation of vascular tone is one among therapeutic interventions used for the appropriate control of blood pressure as contraction and dilation of blood vessels directly control blood pressure.^[8] Research aimed

at finding better therapeutic options for CVDs is in progress in many laboratories around the world, and as a result, a large volume of data has been generated. Abnormal vascular reactivity, including impaired endothelium-dependent relaxation and enhanced sensitivity to vasoconstrictors, is a hallmark of hypertensive disease.^[9,10] Therefore, the relaxation of aortic vascular smooth muscles is very crucial in hypertension and other CVDs. Therapeutically, antihypertensive drugs most used ultimately produce vasorelaxation either directly or indirectly.^[11] Although hypertension can be pharmacologically managed, none of available drugs is without risk of adverse reactions. They instead tend to “control” the condition, while helping extend one’s life.^[12] Therefore, the discovery of new, effective, and safe natural vasodilators relevant

Access this article online

Website: jprsolutions.info

ISSN: 0975-7619

¹International Education College, College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Nankai District, Tianjin, P.R. China, ²School of Pharmacy, Mount Kenya University, Thika, Kenya, ³Faculty of Science, Egerton University, Egerton, Kenya

*Corresponding author: Rosette Uzayisenga, School of Pharmacy, Mount Kenya University, P.O. Box 342-0100, Thika, Kenya. E-mail: rosettesenga@gmail.com

Received on: 23-02-2018; Revised on: 26-03-2018; Accepted on: 29-04-2018

to clinical use would be a great relieve to millions of people since CVD, especially hypertension, seems to represent a serious burden to the entire world.

Medicinal plants have since ages been used to manage hypertension with minimal side effects.^[13,14] They have been of central focus for the screening of newer and better treatment of health problems, especially cardiac diseases.^[15] In this regard, PN has been reported to be one of the promising medicinal herbs with antihypertensive potential.^[16] Qualified as “the miracle root for the preservation of life,” PN is among the most used herbs to prevent and treat CVD, either alone or in combination.^[17-19] Clinically, PN has shown considerable potential in the treatment of coronary heart disease, stroke, inflammation, and immunological disease.^[20-22]

PN and its components were found to possess several beneficial actions on the cardiovascular system including protection of cardiac ischemia,^[23] calcium (Ca²⁺) channel blockade,^[24] and inhibition of platelet aggregation.^[25] PN root is considered as unique herb for its distinct clinical usage^[26] and for its high contents in Rb1, Rd, and Rg1 levels.^[27]

Panax notoginseng saponins (PNS), the major components of PN,^[28,29] include more than 30 different types of saponins,^[30,31] among which ginsenosides Rb1, Rg1, Rd, and notoginsenoside R1 are found in the highest content.^[32,33] Based on their chemical structures, Rg1, R1, and Re are classified as protopanaxatriol (PTS)-type saponins whereas Rb1 and Rd are categorized as protopanaxadiol (PDS)-type and they act through generation of NO inside cells.^[34-37] Rg1 is reported to possess the ability to agonize glucocorticoid receptors which once activated can produce rapid NO in human umbilical vein endothelial cells (HUVECs).^[38,39]

Hypotensive potential of PN total extract has been demonstrated in spontaneously hypertensive rats (SHR) by lowering blood pressure while ginsenosides Rb1 and Rg1 cause endothelium-dependent relaxation in mouse coronary arteries, through activation of NO in endothelial cells.^[16] However, up to date vascular effects and mechanisms of either PDS or PTS, the two main saponin fractions from roots of PN have not yet been demonstrated. This study, therefore, investigated their vascular activities on rat isolated aortic rings and elucidated possible associated signaling pathways.

MATERIALS AND METHODS

All chemical reagents used were obtained from Sigma-Aldrich Inc., St. Louis, MO, USA. PDS and PTS fractions were provided by Zhejiang University, School of Pharmacology. Distilled water was used to dissolve all used drugs except indomethacin and

1H-[1,2,4]-oxadiazole-[4,3- α]-quinoxaline-1-one (ODQ) whose dissolution required dimethyl sulfoxide. The modified Krebs–Henseleit (K–H) solution was used as bath solution. Radnoti Tissue-Organ bath instrument (ADInstruments) was used to perform Tissue-Organ bath experiments, and tensions induced in isolated rat aortic rings were recorded by the help of PowerLab system (ADInstruments PowerLab 8/30, Model ML 870, Australia).

Preparation of Aortic Rings

Male Wistar rats (250–300 g) were executed by decapitation. Following decapitation, the descending thoracic aorta was carefully excised and placed in modified K–H solution pre-cooled at 4°C (pH 7.4) from where the aorta was carefully cleaned of fat, connective tissues and cut into 2–3 mm ring segments (Mary, 1999). For the intact aortic rings, the endothelium remained intact and caution taken to avoid injury to EC. For the denuded rings, endothelium was removed by gently rubbing the luminal surface of the ring with a roughed polyethylene tube.

Measuring of Isometric Vascular Tone

The aortic rings were mounted between two stainless steel wires into a tissue bath (Radnoti Glass Technology) filled with 10 ml of modified K–H buffer which was maintained at 37°C (pH 7.4) and gassed continuously with a 95% O₂ and 5% CO₂ mixture. The rings were allowed to equilibrate for at least 60 min under the resting force of 2.0 g. During the equilibration period, the buffer was routinely changed every 15 min to prevent the accumulation of metabolites.^[40] Tensions were recorded by the help of AD instrument PowerLab 8/30 system.

Experimental Protocol

After equilibration period, the viability of rings was checked by pre-treatment with KCL 60 mM. This was followed by washing out and stabilizing in modified K–H buffer followed by pre-contraction with norepinephrine (NE) 1 μ M. At the plateau phase, the existence of intact endothelium was verified by the ability of acetylcholine (ACh) 10 μ M to induce relaxation on 1 μ M NE-contracted rings. Rings were considered to be functionally denuded of endothelium if vasorelaxation to ACh (10 μ M) was <10%.^[41] Pre-contracted rings (intact or denuded) were randomly exposed to cumulative concentrations of either PDS or PTS fractions to evaluate their relaxant effects.

Effect of Endothelium in PDS- and PTS-Induced Relaxations

To assess the role of endothelium on PDS- and PTS-induced relaxations, experiments were run on denuded rings.

Investigating Mechanisms underlying Vasorelaxant Effect of PDS and PTS

NO and cyclooxygenase (COX) pathways

To assess the role of NO and COX pathways, the two fractions (PDS and PTS) were pretreated with different inhibitors including indomethacin (10 μ M), a COX inhibitor, a NO synthase inhibitor, and L-NAME (100 μ M). Each of these inhibitors was incubated in the bath for 20–30 min before adding 1 μ M NE to increase the tone.

NO/cyclic guanosine monophosphate (cGMP) pathways

The role of NO/cGMP pathways was investigated using either ODQ (10 μ M) alone or a combination of both ODQ (10 μ M) and L-NAME (100 μ M).

Effect of PDS and PTS on KCL Responses

To investigate the impact of these two fractions on cumulative responses of KCL (7.5–60 mM), denuded tissues (rings) were incubated with either PDS or PTS (10^{-4} and 10^{-3} μ g/ml) for 20 min and their effect was evaluated by comparing levels of KCL-induced contractility in the presence and absence of both PDS and PTS separately.

Effect of PDS and PTS Fractions on Extracellular Ca^{2+} Ions Influx

To assess the effect of PDS and PTS fractions on cumulative responses of CaCl_2 (10^{-3} – $10^{-1.5}$ M), denuded rings were bathed with Ca^{2+} -free, highly concentrated KCL (80 mM) Krebs solution then incubated with either PDS or PTS (10^{-4} and 10^{-3} μ g/ml) for 30 min and their effect was assessed by comparing contractions produced by CaCl_2 before and after incubation with either PDS or PTS.

Data and Statistical Analysis

All values are expressed as means \pm standard deviation error. Relaxant responses are presented as percentage change in tension from pre-constriction levels. Data analysis was done by the help of one-way ANOVA followed by separation of means by Bonferroni *post-hoc* test (SPSS version 16.0). $P \leq 0.05$ was considered statistically significant. GraphPad Prism 5 was used for curve fitting.

RESULTS

Vascular Relaxant Effects of PDS and PTS

Both PDS and PTS induced dose-dependent relaxations in endothelium-intact rings.

To ascertain whether this activity was endothelium dependent, the same experiments were carried out on denuded rings and it was observed that endothelium removal significantly reduced PDS and PTS relaxations [Figure 1].

Effect of L-NAME, ODQ, L-NAME+ODQ, and Indomethacin on PDS-and PTS-Induced Vascular Relaxations

Our findings show that PDS- and PTS-induced relaxations were significantly reduced in endothelium-intact rings pre-treated with L-NAME (100 μ M), ODQ (10 μ M), and combination of ODQ with L-NAME. It was observed that L-NAME and ODQ combined further decreased these effects compared with L-NAME alone. However, PDS and PTS effect in intact tissues pre-treated with indomethacin persisted [Figures 1 and 2].

The Effect of PDS and PTS on CaCl_2 - and KCL-Induced Vasoconstrictions

This study shows that pre-treatment of endothelium-denuded rings with PDS and PTS (10^{-4} and 10^{-3} μ g/ml) significantly reduced the potency of contractile responses to CaCl_2 and KCL [Figures 3 and 4].

DISCUSSION

This study has demonstrated that both PDS and PTS, the major saponin fractions isolated from roots of PN, induce vasorelaxation of NE pre-contracted rat aortic rings in a dose-dependent manner. This effect disappeared in the absence of functional endothelium. Our findings suggest that PDS and PTS dilate vascular smooth muscle through endothelium-dependent NO-cGMP pathway.

The vascular endothelium plays an important role in the regulation of cardiovascular functions, mainly in controlling vascular tone through synthesis and release of endothelium-derived relaxing factors, such as NO and prostacyclin (PGI_2). Impaired endothelial function, with reduced NO activity, is associated with CVDs, including hypertension.^[42,43] In this regard, this study first investigated the role of functional endothelium in either PDS- or PTS-induced vasorelaxation and it was found that the removal of the functional endothelium abolished their relaxant effects [Figure 1b and c). Thus, we suggest that PDS- and PTS-induced relaxations were dependent on the presence of endothelium.

This study also investigated the involvement of NO release in relaxant effects of both PDS and PTS and it was found that their relaxant effects were significantly decreased in endothelium-intact rings pre-treated with L-NAME [Figure 2], indicating the contribution of NO in PDS and PTS effect which in particular supports the clinical use of PN in the management of CVD, especially hypertension in traditional Chinese medicine (TCM). These findings are consistent with a previous study that showed that both PN extract and the major compounds Rb1 and Rg1 increase NO

production in mouse coronary arteries.^[44-48] Based on this, we can conclude that the vasorelaxant effect caused by both PDS and PTS is NO mediated.

It has been demonstrated that several stimulants activate soluble guanylyl cyclase (sGC) resulting in the formation of cGMP whose intracellular accumulation signals protein kinases, ion channels, and other effector systems causing smooth muscle relaxation.^[49-53] In our experiments, ODQ, a specific sGC inhibitor, markedly attenuated vasorelaxant effect of both PDS and PTS and this was further decreased by combination of




Figure 1: Vasorelaxant effects of protopanaxadiol (PDS) and protopanaxatriol (PTS) with or without endothelium. (a) PDS and PTS with endothelium, (b) PDS with and without endothelium, (c) PTS with and without endothelium. Data are shown as mean \pm SEM of five independent experiments. SEM: Standard deviation error




Figure 2: Effect of NG-nitro-L-arginine methyl ester (L-NAME), 1H-[1,2,4]-oxadiazole-[4,3- α]-quinoxaline-1-one (ODQ), L-NAME + ODQ, and indomethacin on protopanaxadiol (PDS)- and protopanaxatriol (PTS)-induced vasorelaxation. (a) Effects to PDS, (b) effects to PTS. Data are shown as mean \pm SEM of five independent experiments. SEM: Standard error mean

L-NAME and ODQ [Figure 2]. These findings indicate the involvement of NO and cGMP in PDS and PTS vasorelaxant activity, suggesting that their relaxant effect is induced through NO-cGMP pathway.




Figure 3: Effect of protopanaxadiol (PDS) and protopanaxatriol (PTS) on CaCl₂-induced contractions in endothelium-denuded rat aortic rings depolarized by 80 mM KCL. (a) Effect of PDS, (b) effect of PTS. Data are shown as mean \pm SEM of five independent experiments. SEM: Standard error mean




Figure 4: Effect of protopanaxadiol (PDS) and protopanaxatriol (PTS) on KCL-induced contractions in endothelium-denuded rat aortic rings. (a) Effect of PDS, (b) effect of PTS. Data are shown as mean \pm SEM of five independent experiments. SEM: Standard error mean

The possible role of PGI₂ in PDS and PTS vasodilatations was also assessed in intact rings pre-treated with indomethacin. It was found that the presence of indomethacin does not affect the vasorelaxant effect caused by both PDS and PTS. Indomethacin is well known to possess the potential of blocking PGI₂ formation by inhibiting COX.^[54] These findings, therefore, indicate non-contribution of vasoactive PGI₂ to PDS- and PTS-induced relaxations.

To further investigate possible mechanisms, we determined the role of Ca²⁺ in vasorelaxant effect of these fractions, and our findings demonstrated that both PDS and PTS significantly reduced Ca²⁺-induced contractions of K⁺-depolarized aortic rings and KCL-induced contractions. It has been confirmed that cytosolic Ca²⁺ increases during contraction of vascular smooth muscles either as a consequence of influx of Ca²⁺ from the extracellular space or release of Ca²⁺ from intracellular stores whereas relaxation is accompanied by a decrease in the cytosolic calcium influx level in smooth muscle cells.^[53] Furthermore, it is also known that both potassium- and Ca²⁺ chloride-induced contractions of vascular smooth muscle are dependent on extracellular Ca²⁺ ions.^[55-57] Therefore, findings from this study indicate that both PDS and PTS block the passage of extracellular Ca²⁺ ions across the vascular smooth membranes, suggesting that their vasorelaxant effect is mainly due to the inhibition of Ca²⁺ influx from the extracellular space.

CONCLUSION

This study has demonstrated that both PDS and PDS, major saponin fractions from roots of PN, cause endothelium-dependent relaxation through NO-cGMP, and in the vascular smooth muscle, they inhibit calcium influx from the extracellular space. COX pathway, on the other hand, had no apparent role. This suggests that their responses may be mainly due to the inhibition of voltage-dependent Ca²⁺ channels. Among these fractions, PDS shows better effect than PTS even though the difference is not statistically significant. These findings support the potential use of PN in the management of CVD, especially hypertension.

Further Directions

Further studies should assess possible involvement of K⁺ channels in PDS- and PTS-induced vasorelaxation using various specific K⁺ channel inhibitors such as charybdotoxin, iberiotoxin, or apamin.

ACKNOWLEDGMENT

This study was entirely sponsored by the Chinese Scholarship Council, through the International Education College, Tianjin University of Traditional Chinese Medicine, P.R. China.

REFERENCES

1. Pratt C. Alternative prevention and treatment of cardiovascular disease, Part 2. *Primary Care* 2010;37:339-66.
2. Goyal S, Siddiqui MK, Siddiqui KM, Arora S, Mittal R, Joshi S, *et al.* Cardioprotective effect of 'Khamira Abresham Hakim Arshad Wala' a unani formulation in isoproterenol-induced myocardial necrosis in rats. *Exp Toxicol Pathol* 2010;62:61-74.
3. Houston MC, Fazio S, Chilton FH, Wise DE, Jones KB, Barringer TA, *et al.* Nonpharmacologic treatment of dyslipidemia. *Prog Cardiovasc Dis* 2009;52:61-94.
4. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, *et al.* Prevalence of hypertension in the US adult population. Results from the third national health and nutrition examination survey, 1988-1991. *Hypertension* 1995;25:305-13.
5. Carretero OA, Oparil S. Essential hypertension. Part I: Definition and etiology. *Circulation* 2000;101:329-35.
6. Gupta AK, McGlone M, Greenway FL, Johnson WD. Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile. *Hypertens Res* 2010;33:905-10.
7. Zhang Y, Janssens SP, Winkler K, Schmidt HH, Moens AL. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. *Amer J Physiol Heart Circ Physiol* 2011;301:H634-646.
8. Lincoln TM, Cornwell TL, Taylor AE. CGMP-dependent protein kinase mediates the reduction of ca²⁺ by cAMP in vascular smooth muscle cells. *Am J Physiol* 1990;258:C399-407.
9. Lima VV, Giachini FR, Choi H, Carneiro FS, Carneiro ZN, Fortes ZB, *et al.* Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation. *Hypertension* 2009;53:166-74.
10. Adeagbo AS, Zhang X, Patel D, Joshua IG, Wang Y, Sun X, *et al.* Cyclo-oxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension. *J Hypertens* 2005;23:1025-36.
11. Bankar GR, Nandakumar K, Nayak PG, Thakur A, Chamallamudi MR, Nampurath GK, *et al.* Vasorelaxant effect in rat aortic rings through calcium channel blockage: A preliminary *in vitro* assessment of a 1,3,4-oxadiazole derivative. *Chem Biol Interact* 2009;181:377-82.
12. Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K. Axonal and dendritic extension by protopanaxadiol-type saponins from ginseng drugs in SK-N-SH cells. *Jpn J Pharmacol* 2002;90:254-62.
13. Chan P, Tomlinson B, Chen YJ, Liu JC, Hsieh MH, Cheng JT, *et al.* A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. *Br J Clin Pharmacol* 2000;50:215-20.
14. Greenway F, Liu Z, Yu Y, Gupta A. A clinical trial testing the safety and efficacy of a standardized eucommia ulmoides oliver bark extract to treat hypertension. *Altern Med Rev* 2011;16:338-47.
15. Altaf R, Asmawi MZ, Dewa A, Umar MI. Sources and possible mechanisms of action of important phytoconstituents with cardiovascular properties. *Afr J Pharm Pharmacol* 2012;6:563-80.
16. Pan C, Huo Y, An X, Singh G, Chen M, Yang Z, *et al.* *Panax notoginseng* and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation. *Vascul Pharmacol* 2012;56:150-8.
17. Zhang W, Wojta J, Binder BR. Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. *Arterioscler Thromb* 1994;14:1040-6.
18. Ji W, Gong BQ. Hypolipidemic effects and mechanisms of *Panax notoginseng* on lipid profile in hyperlipidemic rats. *J Ethnopharmacol* 2007;113:318-24.
19. Ling S, Dai A, Guo Z, Komesaroff PA. A preparation of herbal medicine *salvia miltiorrhiza* reduces expression of intercellular adhesion molecule-1 and development of atherosclerosis in

- apolipoprotein E-deficient mice. *J Cardiovasc Pharmacol* 2008;51:38-44.
20. Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. *J Nutr* 2007;137:183S-185S.
 21. Xia ZY, Liu XY, Zhan LY, He YH, Luo T, Xia Z, *et al.* Ginsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflammatory response after cardiopulmonary bypass in patients with congenital heart disease. *J Thorac Cardiovasc Surg* 2005;130:258-64.
 22. Zhang YG, Zhang HG, Zhang GY, Fan JS, Li XH, Liu YH, *et al.* *Panax notoginseng* saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. *Clin Exp Pharmacol Physiol* 2008;35:1238-44.
 23. Li H, Deng CQ, Chen BY, Chen R, Zhang S, Liang Y. Effects of *Panax notoginseng* saponins on expression of caspase after focal cerebral ischemia-reperfusion in rats. *Chinese Pharmacol Bull* 2006;22:189.
 24. Guan YY, Zhou JG, Zhang Z, Wang GL, Cai BX, Hong L, *et al.* Ginsenoside-rd from *Panax notoginseng* blocks Ca^{2+} influx through receptor- and store-operated Ca^{2+} channels in vascular smooth muscle cells. *Eur J Pharmacol* 2006;548:129-36.
 25. Ma LY, Xiao PG. Effects of *Panax notoginseng* saponins on platelet aggregation in rats with middle cerebral artery occlusion or *in vitro* and on lipid fluidity of platelet membrane. *Phytother Res* 1998;12:138-40.
 26. Cui XM, Lo CK, Yip KL, Dong TT, Tsim KW. Authentication of *Panax notoginseng* by 5S-rRNA spacer domain and random amplified polymorphic DNA (RAPD) analysis. *Planta Med* 2003;69:584-6.
 27. Taira S, Ikeda R, Yokota N, Osaka I, Sakamoto M, Kato M, *et al.* Mass spectrometric imaging of ginsenosides localization in *Panax ginseng* root. *Am J Chinese Med* 2010;38:485-93.
 28. Wang CZ, Xie JT, Zhang B, Ni M, Fishbein A, Aung HH, *et al.* Chemopreventive effects of *Panax notoginseng* and its major constituents on SW480 human colorectal cancer cells. *Int J Oncol* 2007;31:1149-56.
 29. Wang CZ, McEntee E, Wicks S, Wu JA, Yuan CS. Phytochemical and analytical studies of *Panax notoginseng* (Burk.) F.H. Chen. *J Nat Med* 2006;60:97-106.
 30. Du Q, Jerz G, Waibel R, Winterhalter P. Isolation of dammarane saponins from *Panax notoginseng* by high-speed counter-current chromatography. *J Chromatogr A* 2003;1008:173-80.
 31. Dong TT, Cui XM, Song ZH, Zhao KJ, Ji ZN, Lo CK, *et al.* Chemical assessment of roots of *Panax notoginseng* in china: Regional and seasonal variations in its active constituents. *J Agric Food Chem* 2003;51:4617-23.
 32. Li L, Sheng Y, Zhang J, Guo D. Determination of four active saponins of *Panax notoginseng* in rat feces by high-performance liquid chromatography. *J Chromatogr Sci* 2005;43:421-5.
 33. Li L, Zhang JL, Sheng YX, Guo DA, Wang Q, Guo HZ, *et al.* Simultaneous quantification of six major active saponins of *Panax notoginseng* by high-performance liquid chromatography-UV method. *J Pharm Biomed Anal* 2005;38:45-51.
 34. Chen X. Cardiovascular protection by ginsenosides and their nitric oxide releasing action. *Clin Exp Pharmacol Physiol* 1996;23:728-32.
 35. Kang SY, Schini-Kerth VB, Kim ND. Ginsenosides of the protopanaxatriol group cause endothelium-dependent relaxation in the rat aorta. *Life Sci* 1995;56:1577-86.
 36. Kim ND, Kim EM, Kang KW, Cho MK, Choi SY, Kim SG, *et al.* Ginsenoside rg3 inhibits phenylephrine-induced vascular contraction through induction of nitric oxide synthase. *Br J Pharmacol* 2003;140:661-70.
 37. Kim H, Chen X, Gillis CN. Ginsenosides protect pulmonary vascular endothelium against free radical-induced injury. *Biochem Biophys Res Commun* 1992;189:670-6.
 38. Leung KW, Cheng YK, Mak NK, Chan KK, Fan TP, Wong RN, *et al.* Signaling pathway of ginsenoside-rg1 leading to nitric oxide production in endothelial cells. *FEBS Lett* 2006;580:3211-6.
 39. Leung KW, Pon YL, Wong RN, Wong AS. Ginsenoside-rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cells. *J Biol Chem* 2006;281:36280-8.
 40. Altura BM, Altura BT. Heterogeneity of drug receptors in different segments of rabbit thoracic aorta. *Eur J Pharmacol* 1970;12:44-52.
 41. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980;288:373-6.
 42. Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. *Circ J* 2009;73:595-601.
 43. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. *Acta Physiol (Oxf)* 2009;196:193-222.
 44. Chiou WF, Chang PC, Chou CJ, Chen CF. Protein constituent contributes to the hypotensive and vasorelaxant activities of *Cordyceps sinensis*. *Life sciences* 2000;66:1369-76.
 45. Kim SH, Kang KW, Kim KW, Kim ND. Procyanidins in crataegus extract evoke endothelium-dependent vasorelaxation in rat aorta. *Life Sci* 2000;67:121-31.
 46. Xie YW, Ming DS, Xu HX, Dong H, But PP. Vasorelaxing effects of caesalpinia sappan involvement of endogenous nitric oxide. *Life Sci* 2000;67:1913-8.
 47. Goto H, Sakakibara I, Shimada Y, Kasahara Y, Terasawa K. Vasodilator effect of extract prepared from *Uncariae ramulus* on isolated rat aorta. *Am J Chinese Med* 2000;28:197-203.
 48. Tanner MA, Bu X, Steimle JA, Myers PR. The direct release of nitric oxide by gypenosides derived from the herb *Gynostemma pentaphyllum*. *Nitric Oxide* 1999;3:359-65.
 49. Kukovetz WR, Holzmann S, Romanin C. Mechanism of vasodilation by nitrates: Role of cyclic GMP. *Cardiology* 1987;74 Suppl 1:12-9.
 50. Medina P, Segarra G, Vila JM, Domenech C, Martínez-León JB, Lluç S, *et al.* Effects of sildenafil on human penile blood vessels. *Urology* 2000;56:539-43.
 51. Mochida H, Inoue H, Takagi M, Noto T, Yano K, Kikkawa K, *et al.* Sildenafil and T-1032, phosphodiesterase Type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. *Eur J Pharmacol* 2002;440:45-52.
 52. Tarpey MM, Beckman JS, Ischiropoulos H, Gore JZ, Brock TA. Peroxynitrite stimulates vascular smooth muscle cell cyclic GMP synthesis. *FEBS Lett* 1995;364:314-8.
 53. Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction. *Physiol Rev* 1996;76:967-1003.
 54. Gordon JL, Martin W. Stimulation of endothelial prostacyclin production plays no role in endothelium-dependent relaxation of the pig aorta. *Br J Pharmacol* 1983;80:179-86.
 55. Altura BM, Altura BT. Peripheral vascular actions of glucocorticoids and their relationship to protection in circulatory shock. *J Pharmacol Exp Ther* 1974;190:300-15.
 56. Bohr DF. Vascular smooth muscle updated. *Circ Res* 1973;32:665-72.
 57. Godfraind T, Kaba A. Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. *Br J Pharmacol* 1969;36:549-60.

Source of support: Nil; Conflict of interest: None Declared